Dual biologic therapy with Omalizumab and Dupilumab for refractory atopic disease

Arasu, Alexis; Sharma, Naomi L.; Yazdabadi, Anousha; Sladden, Michael J

doi:10.1111/ajd.13743

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 The observational data available show modest evidence for safety and efficacy, none of which have investigated the use of dupilumab and fremanezumab specifically. [3][4][5] Here, we have found dupilumab and fremanezumab to be effective combination therapy with no adverse interactions over a 6-month period, although longer follow-up is required. This adds to the literature suggesting that dual biological therapy may not increase risk or impair the patient's clinical response.…”

mentioning

confidence: 79%

The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab

Honigman,

Oo,

Macdonell

et al. 2024

Aust J Dermatology

View full text Add to dashboard Cite

mentioning

confidence: 79%

The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab

Honigman,

Oo,

Macdonell

et al. 2024

Aust J Dermatology

View full text Add to dashboard Cite

“…Its use in severe pediatric AD has been tested in a randomized clinical trial concluding that omalizumab is a treatment option for difficult-to-manage severe eczema in children with atopy (163). Omalizumab application in IEIs-A is limited to case reports or single clinical experience in particular in HIES with concomitant respiratory manifestations, but this application is still debated (63,(163)(164)(165)(166).…”

Section: Discussionmentioning

confidence: 99%

Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement

et al. 2023

View full text Add to dashboard Cite

Inborn errors of immunity associated with atopy (IEIs-A) are a group of inherited monogenic disorders that occur with immune dysregulation and frequent skin involvement. Several pathways are involved in the pathogenesis of these conditions, including immune system defects, alterations of skin barrier and metabolism perturbations. Current technological improvements and the higher accessibility to genetic testing, recently allowed the identification of novel molecular pathways involved in IEIs-A, also informing on potential tailored therapeutic strategies. Compared to other systemic therapy for skin diseases, biologics have the less toxic and the best tolerated profile in the setting of immune dysregulation. Here, we review IEIs-A with skin involvement focusing on the tailored therapeutic approach according to their pathogenetic mechanism.

show abstract

“…Moreover, atopic diseases share a common inflammatory pathway with prurigo involving the IL-4/13 molecule factor, which plays a role in developing pruritus and the Th2 inflammatory reaction [34–36]. The efficacy of dupilumab (IL-4/13 blocker) in atopic diseases and CPG also confirms their cross-relationships [10, 37–39]. Further, CPG treatment is based on a step-by-step approach [2].…”

Section: Discussionmentioning

confidence: 99%

Comorbidities of Chronic Prurigo: A Systematic Review and Meta-Analysis

Yin,

Yang,

Guo

et al. 2023

Dermatology

View full text Add to dashboard Cite

Background: Chronic prurigo (CPG) is an inflammatory skin disease. Comorbidities including dermatological, cardiovascular, and psychiatric diseases have been reported in patients with CPG, however, the evidence has not been systematically evaluated. We aim to summarize the comorbidities, discuss underlying pathogenesis, and highlight the evaluation of CPG patients. Methods: We performed a systematic search using PubMed, Embase, and Web of Science databases for all articles reporting possible associated diseases with CPG. Pooled random-effects odds ratios (OR) with 95% CI were calculated. Results: A total of 17 studies were included in this systematic review. Statistically significant association(P<0.05) with CPG has been demonstrated with atopic diseases: atopic dermatitis (pooled OR, 10.91; 95% CI, 3.65-32.67), allergic rhinitis (2.66;1.12-6.27), asthma (3.23;1.55-6.74); infectious diseases: hepatitis B (pooled OR, 2.15; 95% CI, 1.11-4.14); endocrine diseases: diabetes (pooled OR, 4.93; 95% CI, 1.13-21.56), type 1 diabetes 2.46;2.16-2.81), type 2 diabetes (1.89;1.34-2.68), hyperlipoproteinemia (2.90; 1.61-5.22); cardiovascular diseases: heart failure (pooled OR, 4.13; 95% CI, 1.15-14.91), hypertension (3.17;1.56-6.45); respiratory system diseases: chronic obstructive pulmonary disease (pooled OR, 3.19; 95% CI, 1.42-7.16); urinary system diseases: chronic kidney disease (pooled OR, 4.16; 95% CI, 1.79-9.66); digestive system disease: inflammatory bowel disease (pooled OR, 2.06; 95% CI, 1.26-3.36); and others: osteoporosis (pooled OR, 3.08; 95% CI, 1.70-5.59), thyroid disease (1.70;1.17-2.47). Conclusion: CPG is associated with various systemic disorders. Recognition of comorbidities is critical to the appropriate management of affected patients.

show abstract

Dual biologic therapy with Omalizumab and Dupilumab for refractory atopic disease

Abstract: Sciences approved this study (IR.SBMU.MSP. REC.1397.408).

Cited by 4 publications

References 10 publications

The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab

The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab

Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement

Comorbidities of Chronic Prurigo: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About